Evidence map›Paper›PMID 32173794›Full record

ArticleAdvances in therapy2020

Response to "Comment on Retrospective Claims Analysis Indirectly Comparing Medication Adherence and Persistence Between Intravenous Biologics and Oral Small-Molecule Therapies in Inflammatory Bowel Diseases".

Kellyn Moran, Kyle Null, Zhongwen Huang, Trevor Lissoos, Sunanda Kane

Open access · hybridAbstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Kellyn MoranU.S. Medical Affairs, Takeda Pharmaceuticals U.S.A., Inc., Deerfield, IL, USA.
Kyle NullU.S. Medical Affairs, Takeda Pharmaceuticals U.S.A., Inc., Deerfield, IL, USA.
Zhongwen HuangU.S. Medical Affairs, Takeda Pharmaceuticals U.S.A., Inc., Deerfield, IL, USA.
Trevor LissoosU.S. Medical Affairs, Takeda Pharmaceuticals U.S.A., Inc., Deerfield, IL, USA.
Sunanda KaneDivision of Gastroenterology and Hepatology Department of Medicine, Mayo Clinic, Rochester, MN, USA. Kane.Sunanda@mayo.edu.
Takeda (United States) · USMayo Clinic in Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Biological ProductsInflammatory Bowel DiseasesHumansInsurance Claim ReviewMedication AdherenceRetrospective StudiesBiological ProductsIBDInflammatory bowel diseaseIntravenous biologicsOral small-molecule therapies

Identifiers

PMID32173794
PMCPMC7140747
OpenAlexW3010729080

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.